SGTX
Sigilon Therapeutics Inc (SGTX)
$0.83
Key Stats
$0.781001
Day's Range
$0.88
$0.7303
52-Week Range
$10.96
| Returns | |
| 1 month return | 8.88% |
| 3 month return | 49.39% |
| 1 year return | 91.47% |
| 5 year return | 97.61% |
Company Information
Sigilon Therapeutics seeks to develop functional cures for chronic diseases through its Shielded Living Therapeutics™ platform. Sigilon’s product candidates are non-viral engineered cell-based therapies designed to produce the crucial proteins, enzymes or factors needed by patients living with chronic diseases such as hemophilia, lysosomal disorders and diabetes. The engineered cells are protected by Sigilon’s Afibromer™ biomaterials matrix, which shields them from immune rejection and fibrosis. Sigilon was founded by Flagship Pioneering in conjunction with Daniel Anderson, Ph.D., and Robert Langer, Sc.D., of the Massachusetts Institute of Technology.
| Organization | Sigilon Therapeutics Inc |
| Employees | 2021 |
| CEO |
Analyst Recommendation
based on 11 analysts ratings
Buy
72%
Buy
27%
Hold
0%
Sell
Based on 11 Wall street analysts offering stock ratings for Sigilon Therapeutics Inc(by analysts ranked 0 to 5 stars)
Analyst Forecast
What analysts predicted
Upside of 743.37%Current
$0.83
Target
$7.0
Recommendation Trend
Based on 11 analyst
| Current | 1M Ago | 3M Ago | |
| Buy | 8 | 8 | 8 |
| Hold | 3 | 3 | 3 |
| Sell | 0 | 0 | 0 |
| Consensus | BUY | BUY | BUY |
Company Financials
Highlights
| Market Capitalization | 34.7M |
| Book Value | 2.38 |
| Dividend Share | 0.0 |
| Dividend Yield | 0.0 |
| Earnings Share | -2.43 |
| Wall Street Target Price | 4.12 |
Valuation
| Trailing PE | 0.0 |
| Forward PE | 2.77 |
| Price/Sales (ttm) | 3.61 |
| Price/Book (mrq) | 0.52 |
| Enterprise Value | -50004914 |
| Enterprise Value/Revenue | 1.46 |
| Enterprise Value/Ebitda | 0.67 |
Technicals
| 50 Day MA | 1.4 |
| 200 Day MA | 3.61 |
Institutional Holdings
Flagship Ventures Management, Inc.
32.01%
BlackRock Inc
5.36%
Canada Pension Plan Investment Board
4.58%
FMR Inc
3.29%
Harbourvest Partners, LLC
2.29%
State Of Wisconsin Investment Board
1.57%
